(C) Human YY2 sequence. YY2 amino-terminus (YY2 (aa1-226)) (blue); YY2 carboxylterminus (YY2 (aa227-372)) (black); Zn fingers (in parentheses). Lysine residues (K139, K247 and K369) embedded in SET7/9 consensus methylation sites were underlined (red).
(G) Sequence alignment of human YY1 and YY2 by using Clustal Omega. Boxed residue is lysine 247 (K247) in YY2 and its homologous lysine 288 (K288) in YY1. Figure S2 . Effects of SET7/9 or LSD1 on YY2 K247 methylation.
(A) HeLa cells transfected with control siRNA or siRNA specifically targeting SET7/9 or LSD1 in the presence of YY2 were subjected to IB with antibodies as indicated.
(B) Genomic DNA was extracted from LSD1 knock-out (KO) cells generated by CRISPR/Cas9 system, followed by PCR using specific primer sets surrounding gRNA targeting region (boxed in blue). The resultant PCR products were subjected to Sanger sequencing and genomic region with deletions was shown, with one or ten basepair (bp) removed as shown in dash. Translation start codon (ATG) (dark red). (A) HeLa cells were subjected to ChIP analysis as described in Figure. 5D. ChIP signals were presented as fold induction over wt after normalized to input (± s.e.m., *P<0.05, **P<0.01).
(B) The expression of YY2 (wt) and YY2 (K247R) as described in Figure. 5D and (A) was examined through IB.
(C) Control (wt), SET7/9 or LSD1 knockout (KO) HeLa cells were subjected to ChIP analysis as described in Figure. 5E. ChIP signals were presented as fold induction over wt after normalized to input (± s.e.m., **P<0.01, ***P<0.001).
(D) The expression of YY2 as described in Figure. 5E and (C) was examined through IB.
(E) The expression of YY2, SET7/9 (wt), SET7/9 (m), LSD1 (wt) and LSD1 (m) as described in Figure. 5F was examined by IB using antibodies as indicated. (A) Genomic DNA was extracted from YY2 knock-out (KO) cells generated by CRISPR/Cas9 system, followed by PCR using specific primer sets surrounding gRNA targeting region (boxed in blue). The resultant PCR products were subjected to Sanger sequencing and genomic region with deletions was shown, with seven basepair (bp) removed as shown in red. Translation start codon (ATG) (dark red).
(B) HeLa cells were transfected with luciferase reporter containing YY1 consensus binding site (pGL2-YY1-luc) in the presence or absence of control vector or vectors expressing YY2(wt) or YY2 (K247R), followed by luciferase reporter activity measurement (± s.e.m., ***P<0.001).
(C) The expression of YY2 (wt) and YY2 (K247R) as described in (B) was examined through IB with anti-Flag antibody. (C) HeLa cells were subjected to ChIP as described in Figure. 7D. ChIP signals were presented as fold induction over wt after normalized to input (± s.e.m., **P<0.01, ***P<0.001). Table Legend   Table S1 . MS2 spectrum of K139-methylated peptides in YY2. In vitro methylation assay was performed by mixing synthetic short peptide containing YY2 K139 with SET7/9 followed by LC MS/MS analysis. MS2 spectrum of K139-methylated peptide was shown. Table S2 . MS2 spectrum of K247-methylated peptides in YY2 in vitro. In vitro methylation assay was performed by mixing in vitro purified bacterially-expressed YY2 and SET7/9 followed by mass spectrometry (MS) analysis. MS2 spectrums of peptides containing K247-methylation as well as the corresponding unmodified peptides were shown. Table S3 . MS2 spectrum of K247-methylated peptides in YY2 in cultured cells. HeLa cells were transfected with Flag-tagged YY2 and SET7/9, followed by affinity purification and MS analysis. MS2 spectrum of peptide containing K247-methylation as well as the corresponding unmodified peptide was shown. Table S4 . Gene ontology analysis for genes regulated by YY2, SET7/9 or LSD1. Gene ontology analysis for genes regulated, both positively and negatively, by YY2, SET7/9 or LSD1, genes positively regulated by YY2 and SET7/9 in common, and genes positively-regulated by YY2 and SET7/9 in common and negatively-regulated by LSD1 was done using David 68 . Cs TKMKPKRSKGELPKTVPCSHSGCEKMFRDYAAMRKHLHVHGPRVHVCAECGKAFIESSKL 300 **:****** : *:** *:: ** ******.*******:***:****:****:*:***** :.*******:.********:**************:::**:: * .: *:*: * : 
